Emile Nuwaysir, Ph.D., President and CEO 

Oct. 11 | 12:00pm | Oxford Biomedica Ballroom 

Boston, MA 


In-person Presentation 

Ensoma is a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within. The company is poised to create a new therapeutic category addressing complex diseases such as immune-oncology and autoimmunity through multiplex cellular and genetic programming. Ensoma’s platform can uniquely address these disorders by leveraging its unprecedented payload capacity and exquisite specificity to harness powerful HSC biology. Ensoma also has the potential to leapfrog therapies in well-validated indications such as hemoglobinopathies and dramatically expand patient eligibility through its portable in vivo solution. Ensoma launched in 2021 with a $70 million Series A led by 5AM Ventures, with participation from a syndicate of top-tier investors. The company also announced a strategic collaboration with Takeda in rare disease, with the potential for $100 million in upfront and near-term research payments, and total milestones up to $1.25 billion. 


By using this website you agree to accept our Privacy Policy and Terms & Conditions